Submission-ready.
Every deadline. Every time.

The CMS Open Payments annual submission deadline is March 31, with CMS publishing the data on June 30. qordata tracks federal and state deadlines with built-in scheduling, and because data is validated continuously through the year instead of assembled under deadline pressure, submission-ready data is already in place well before the date arrives.

Yes. qordata aggregates spend data from Concur and other T&E systems, ERP systems, CRO and R&D platforms, Medical Affairs data and third-party HCP spend into a single pipeline, replacing the manual, once-a-year reconstruction most compliance teams dread. Spend on the same HCP often originates in several disconnected systems, which is why the most reliable approach consolidates them automatically.

Reportable spend includes payments and transfers of value covered under CMS Open Payments and state transparency laws, such as consulting fees, meals, travel and research grants, while non-reportable spend falls under exemptions like de minimis thresholds or categories a jurisdiction excludes. In qordata, fields are mapped from each source system and business rules are defined up front, so the logic for what counts as reportable and which jurisdiction's rules apply stays consistent and documented, and AI-driven classification applies it uniformly across large datasets instead of being decided ad hoc during report season.

Yes. qordata runs scheduled monthly or quarterly pulls that validate completeness and accuracy, including entity validation for healthcare professionals, non-physician practitioners and healthcare organizations, catching mismatched or incomplete recipient data while there is still time to fix it instead of at submission, when it can cause a rejected or inaccurate report.

Yes. qordata's AI-trained models classify spend as reportable or non-reportable, sort it by category, and analyze for outliers, misclassification and duplicates as a final check on every transaction before submission, catching the exact errors regulators look for while they are still cheap to fix rather than after CMS flags them.

Yes. qordata generates and submits fully compliant CMS Open Payments reports and state-specific reports through each program's designated portal, applying one data pipeline to federal and state submissions across states such as Nevada, Minnesota, DC, Oregon, Massachusetts, Connecticut and Vermont, rather than running separate processes per jurisdiction.

Companies can use CMS's dispute and correction process during the annual review period to resolve flagged errors before the data is finalized for publication, and because that window is time-limited, building error resolution into the workflow matters. qordata supports the full post-submission cycle, including CMS error resolution, dispute resolution support and analytical reporting, so issues that surface after submission or publication get handled inside the same workflow instead of a separate scramble.

Significantly. When engagements are captured compliantly in qordata's EngageAgent and 100% of expenses are audited in EMA, the spend feeding transparency reporting is already clean, so reporting becomes a straightforward output instead of a reconstruction project every season.

Leading options are AI-enhanced platforms purpose-built for CMS Open Payments (Sunshine Act, Section 6002) validation and submission, such as qordata's Transparency Reporting Solution, alongside broader multi-country compliance suites.

States with their own pharmaceutical spend transparency reporting requirements beyond the federal Sunshine Act include Nevada, Minnesota, the District of Columbia, Oregon, Massachusetts, Connecticut, and Vermont, each with distinct deadlines, covered recipients, and data fields. Companies operating across multiple states typically need a system that tracks each state's rules separately rather than assuming one federal process covers all of them.

The strongest tools aggregate spend data from T&E, ERP, and CRM systems, apply data mapping and business rules, run validation and entity checks, and auto-classify reportable vs. non-reportable spend. qordata's Transparency Reporting Solution automates this end-to-end process with AI-trained models that also flag outliers, misclassifications, and duplicates before submission.

Yes. Under ACA Section 6004, manufacturers and authorized distributors of record must separately report the identity and quantity of drug samples requested and distributed, in addition to their CMS Open Payments obligations. According to FDA guidance, the annual report is due by April 1 for the prior calendar year and is submitted in XML through the FDA's Electronic Submissions Gateway. Reporting platforms that cover both obligations reduce the risk of missing one filing while focused on the other.

Applicable pharmaceutical and medical device manufacturers, and group purchasing organizations (GPOs), are required to submit annual CMS Open Payments reports.

Reportable items include consulting fees, compensation for non-consulting services, honoraria, gifts, entertainment, food and beverage, travel and lodging, education, charitable contributions, royalty or license fees, current or prospective ownership or investment interests, faculty or speaker compensation, grants, space or facility rental fees, debt forgiveness, and long-term medical supply or device loans. Research payments are reported separately, in a research payments file within the same annual submission.

Nevada requires pharmaceutical manufacturers to give the Department of Health and Human Services (DHHS) an annual list of their pharmaceutical sales representatives. Each listed representative must then report to DHHS by March 1, covering the preceding calendar year, the health care providers who received compensation above $10 per item or above $100 in total, along with any free drug samples provided.

Minnesota requires drug manufacturers to file an annual report with the Minnesota Board of Pharmacy covering the prior calendar year's payments totaling $100 or more to a practitioner. The report covers payments the state's gift ban permits, such as reasonable faculty honoraria and expenses at professional or educational conferences, and compensation for substantial professional or consulting services on a genuine research project. Practitioners already covered by federal Open Payments are pre-empted, so the Board's guidance currently applies reporting to dental therapists, veterinarians, and independently prescribing pharmacists. The annual filing date is May 1.

Minnesota's gift ban excludes free professional samples that a prescriber distributes to patients for free, items with a total combined retail value of $50 or less in a calendar year, and payments to the sponsor of a medical conference that are not made directly to a practitioner and are used solely for bona fide educational purposes. Faculty honoraria and expenses and research consulting compensation are permitted, but must be reported if they total $100 or more to a practitioner in a year.

D.C.'s AccessRx law requires pharmaceutical manufacturers and labelers to submit an annual report by July 1 covering advertising and promotional expenses and the cost of marketing to D.C. health care professionals, including food, entertainment, gifts valued at more than $25, and other items such as consulting, honoraria, and travel. Marketing expenses of $25 or less per day per provider are excluded, and payments to physicians and teaching hospitals already reported to Open Payments are not reported again. The report is accompanied by a $5,000 filing fee paid by check.

Oregon requires pharmaceutical sales representatives who market or promote to Oregon health care providers for 15 or more days a year to hold a license from the Division of Financial Regulation. Licensed representatives must keep a disclosure log of their marketing and promotional contacts with Oregon providers, whether in person, by email, virtual, or by phone, and the log for a given year is due by April 1 of the following year through the state's iReg portal. Employers may submit on a representative's behalf, and failing to submit can block license renewal.

Massachusetts requires pharmaceutical and medical device manufacturers that employ or contract with sales agents to register with the Department of Public Health and pay a $2,000 annual registration fee. They must also submit an annual disclosure report by July 1 covering the prior calendar year's payments and economic benefits of $50 or more to covered recipients in connection with sales and marketing, such as product training expenses, compensation for CME faculty and speakers' bureau participation, and compensation for bona fide services.

Connecticut requires pharmaceutical manufacturers that employ sales representatives to register annually with the Department of Consumer Protection as pharmaceutical marketing firms, with registrations expiring June 30. Each firm files an annual report by July 1 covering the prior calendar year's contacts with prescribers, their specialties, whether samples, materials or gifts were provided, and an aggregate report of free samples. Separately, Connecticut has an APRN payment report, also due July 1, covering transfers of value to independently practicing advanced practice registered nurses.

Vermont requires pharmaceutical, biological product, and medical device manufacturers to disclose to the Attorney General's Office by April 1 each year their allowable expenditures and gifts to health care providers, academic institutions, nonprofit hospital foundations, and certain professional, educational, and patient organizations, along with free samples, for the prior calendar year. Manufacturers also file an annual compliance officer form by April 1, and those with expenditures above zero pay an annual fee, currently $765.

FDA guidance on ACA Section 6004 describes the data submitted as the drug trade name, strength, dosage and package size, the quantity requested and distributed, and practitioner details such as name, address and professional designation, aggregated by practitioner, plus confirmation that the required signatures are on file. Reports are submitted in XML format through the FDA's Electronic Submissions Gateway.

Yes. Both pharmaceutical and medical device manufacturers, along with group purchasing organizations, fall under CMS Open Payments and most state-level transparency laws.

Cadence varies by requirement: CMS Open Payments and most state laws are annual filings, while the underlying spend data is typically pulled on monthly or quarterly cycles to keep reports current ahead of each deadline.

Yes. Payments below a minimum per-transaction threshold are exempt unless they total more than a slightly higher amount to the same recipient over the year. Both thresholds adjust annually based on the consumer price index, and product samples and patient education materials are separately excluded.

Yes. CMS Open Payments covers physicians, a category that includes medical doctors, doctors of osteopathy, dentists, podiatrists, optometrists, and chiropractors, along with teaching hospitals and non-physician practitioners such as physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives, which were added under a later program expansion. Medical residents and physicians who are employees of the reporting company are excluded.

Manufacturers and GPOs that fail to report can face civil monetary penalties of $1,000 to $10,000 for each payment or transfer of value not reported, up to $150,000 per annual submission. Knowing failures carry penalties of $10,000 to $100,000 per unreported item, up to $1,000,000 per annual submission. Accurate, automated data validation is one of the main ways compliance teams reduce this exposure.

Companies with reporting obligations beyond the U.S. often move to broader multi-country compliance suites that cover dozens of jurisdictions. Companies whose reporting is primarily U.S.-based often prioritize depth and automation for CMS Open Payments and state laws specifically instead, which is what qordata's Transparency Reporting Solution is built for.

The Anti-Kickback Statute prohibits offering or paying remuneration to induce referrals or purchases reimbursable by federal healthcare programs. Many of the same payments that must be disclosed under CMS Open Payments, consulting fees, meals, speaker honoraria, are also the categories of remuneration regulators scrutinize for kickback risk. Transparency reporting doesn't establish Anti-Kickback Statute compliance on its own, but accurate, complete spend data is often the starting point compliance teams use to evaluate that risk.

Yes, indirectly. Safe harbor regulations describe payment arrangements that, when structured correctly, are protected from Anti-Kickback Statute liability even though they involve remuneration to HCPs. Many life sciences companies cross-reference their transparency reporting data against safe harbor criteria to help confirm how a given payment arrangement is classified.